Inhibition of HER2 activity by lapatinib, a dual HER2/EGFR kinase inhibitor, decreased both phosphorylation and expression of CDK7, and phosphorylation of RNA Pol II CTD in the HER2+ BC cell line SKBR3 (Fig. 3c). The gene discussed is ERBB2; the disease is breast cancer.